LENTISOMA is a new generation lentiviral vector whose most outstanding feature is related to the fact that it is not inserted into the genome of cells.
VIVEbiotech, a company specialized in the production of lentiviral vectors for their use in gene therapy, has received notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office.
LENTISOMA is a new generation lentiviral vector whose most outstanding feature is related to the fact that it is not inserted into the genome of cells. This novel mechanism of action provides advantages relative to safety and efficiency with respect to the vectors currently in use.
When its development phase ends, the advantages of LENTISOMA will position it as one of the vectors of choice for the gene therapies that require it.
Therefore, it is very important that LENTISOMA is correctly protected from the Intellectual Property point of view in the United States, bearing in mind that it is the most powerful country in the development of gene therapies.
This concession is consistent with the growing number of manufacturing projects that VIVEbiotech is developing in the US market (6 projects currently).
La industria vasca prevé una afección global a corto-largo plazo imposible aún de cuantificar,...Leer másShare
AseBio brings together more than 730 companies that employ almost 100,000 people and invest more...Leer másShare
VIVEbiotech has carried out a capital increase of 3.5 million euros to finance its...Leer másShare
With the new investment fund, the managers plan to build two new plants in San...Leer másShare
Medical Devices and Digital Health sectors are multidisciplinary areas that need, for their...Leer másShare
For SMEs, for diversifying markets, internships abroad, international tenders, non-reimbursable subsidies to consolidate exports, subsidies for deployments or specific training in internationalisation.You’re interested, right?